A Real-Life Survey of Venous Thromboembolic Events Occurring in Myeloma Patients Treated in Third Line with Second-Generation Novel Agents

A Real-Life Survey of Venous Thromboembolic Events Occurring in Myeloma Patients Treated in Third Line with Second-Generation Novel Agents

Compared to the general population, patients with multiple myeloma (MM) have a nine-fold increased risk of developing venous thromboembolism (VTE). Little is known about VTE prophylaxis in relapsed/refractory (RR) MM patients treated with next generation anti-myeloma drugs, such as pomalidomide (Pom...

Full description

Bibliographic Details
Main Authors: Valeria Calafiore, Silvia Giamporcaro, Concetta Conticello, Alessandra Romano, Marina Parisi, Gaetano Giuffrida, Daniele Tibullo, Francesco Di Raimondo, Salvatore Santo Signorelli
Format: Article
Language:English
Published: MDPI AG 2020-09-01
Series:Journal of Clinical Medicine
Subjects:
multiple myeloma
venous thromboembolic events
pomalidomide
carfilzomib
Online Access:https://www.mdpi.com/2077-0383/9/9/2876

Internet

https://www.mdpi.com/2077-0383/9/9/2876

Similar Items